Exhibit 99.1
ATHERSYS REPORTS SECOND QUARTER 2017 RESULTS
Management to host conference call at 4:30pm EDT today
CLEVELAND, August 9, 2017 – Athersys, Inc. (Nasdaq: ATHX) today announced its financial results for the three months ended June 30, 2017.
Highlights of the second quarter of 2017 and recent events include:
| • | Clinical program for stroke received Final Scientific Advice positive opinion from the European Medicines Device Agency (“EMA”) – establishing alignment between European and U.S. regulators about the potential for approval based on the success of the planned MASTERS-2 study; |
| • | Stroke program awarded Fast Track Designation by U.S. Food & Drug Administration (“FDA”) – meaning that the program is eligible for accelerated approval, priority review and rolling submission of the biologics license application, facilitating timely regulatory review; |
| • | Provided initial shipment of clinical product to HEALIOS K.K. (“Healios”), our partner for stroke in Japan, for its TREASURE study; |
| • | Continued discussions, diligence activities and evaluation of potential partnering opportunities for ischemic stroke and other programs; |
| • | Revenues of $0.7 million recognized for quarter ended June 30, 2017 and net loss of $6.3 million, or $0.06 net loss per share; and |
| • | Cash and cash equivalents balance of $28.6 million at the end of the second quarter. |
“We are pleased to have received the EMA positive opinion for our pivotal MASTERS-2 stroke study and the Fast Track Designation from the FDA earlier in the quarter,” commented Dr. Gil Van Bokkelen, Chairman & CEO at Athersys. “As a result, we have now successfully established regulatory alignment and clarity with respect to the development and approval path for MultiStem® therapy for ischemic stroke for three major pharmaceutical markets – the U.S., Europe and Japan.
“We have continued to advance our preparations for the MASTERS-2 study and intend to be ready for launch later this year, and in parallel, we are pursuing business development and other initiatives to provide adequate funding for this pivotal trial, as well as advancement of our other core programs. Our partnering discussions continue to progress in stroke and other areas and remain an important priority for the company, and the regulatory clarity we have successfully established reinforces our strong development position,” concluded Dr. Van Bokkelen.
Second Quarter Results
Revenues increased to $0.7 million for the three months ended June 30, 2017 from $0.6 million in the comparable period in 2016 due to an increase of $0.3 million in contract revenue primarily from our collaboration with Healios, partially offset by a $0.2 million decrease in grant revenue. Research and development expenses decreased to $4.6 million for the three months ended June 30, 2017 from $5.8 million for the comparable period in 2016. The $1.2 million decrease is primarily associated with decreased clinical and preclinical development costs of $0.9, decreased sponsored research costs of $0.2 million and decreased internal research supplies of $0.2 million, partially offset by a $0.1 million increase in legal and professional fees.
General and administrative expenses increased to $2.2 million for the three months ended June 30, 2017 compared to $2.0 million in 2016. The $0.2 million increase was primarily due to increased legal and professional fees, salaries and benefits, and other contracted services.
Net loss was $6.3 million in 2017, compared to net loss of $7.0 million in 2016. The difference of $0.7 million reflects the above variances, as well as a $0.3 million non-cash decrease in the gain related to the fair value of our warrant liabilities. All outstanding warrants were either exercised or expired as of March 31, 2017.
Cash used in operating activities was $5.7 million during the 2017 second quarter, compared to cash used of $6.5 million in the 2016 second quarter. As of June 30, 2017, we had $28.6 million in cash and cash equivalents, compared to $14.8 million at December 31, 2016, which includes, among other things, the impact of the common stock offering in February 2017.
Conference Call
Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (BJ) Lehmann, President and Chief Operating Officer, will host a conference call today to review the results as follows:
| Date | Wednesday, August 9, 2017 | |
| Time | 4:30 p.m. (Eastern Time) | |
| Telephone access: U.S. and Canada | 800-273-1254 | |
| Telephone access: International | 973-638-3440 | |
| Access code | 51542352 | |
| Live webcast | www.athersys.com, under the Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on August 23, 2017 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 51542352.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face that could cause actual results to differ materially from those implied by forward-looking statements are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, such as the uncertainty regarding regulatory approvals and market acceptance of our product candidates and our ability to generate revenues, including MultiStem for the treatment of ischemic stroke, acute myocardial infarction, spinal cord injury and acute respiratory distress syndrome and other disease indications, including graft-versus-host disease. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: the success of our collaboration with Healios and others, including our ability to reach milestones and receive milestone payments, and whether any products are successfully developed and sold so that we earn royalty payments; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our collaborators’ ability to continue to fulfill their obligations under the terms of our collaboration agreements; the success of our efforts to enter into new strategic partnerships or collaborations and advance our programs; our ability to raise additional capital; results from our MultiStem ongoing and planned clinical trials, including the MASTERS-2 Phase 3 clinical trial and the Healios TREASURE clinical trial in Japan; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials within the expected time frame or at all; changes in external market factors; changes in our industry’s overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
| ATHX-G |
| Contact: |
| William (B.J.) Lehmann |
| President and Chief Operating Officer |
| Tel: (216) 431-9900 |
bjlehmann@athersys.com
Karen Hunady
Corporate Communications
Tel: (216) 431-9900
khunady@athersys.com
David Schull
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
David.schull@russopartnersllc.com
(Tables Follow)
Athersys, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
| June 30, 2017 |
December 31, 2016 |
|||||||
| (Unaudited) | (Note) | |||||||
| Assets |
||||||||
| Cash and cash equivalents |
$ | 28,594 | $ | 14,753 | ||||
| Other current assets |
1,528 | 1,527 | ||||||
| Equipment, net |
2,410 | 2,605 | ||||||
| Deferred tax assets |
191 | 175 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 32,723 | $ | 19,060 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ equity |
||||||||
| Accounts payable and accrued expenses |
$ | 6,205 | $ | 6,875 | ||||
| Deferred revenue |
503 | — | ||||||
| Warrant liabilities |
— | 1,004 | ||||||
| Total stockholders’ equity |
26,015 | 11,181 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 32,723 | $ | 19,060 | ||||
|
|
|
|
|
|||||
Note: The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.
Athersys, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In Thousands, Except Per Share Amounts)
| Three months ended June 30, |
||||||||
| 2017 | 2016 | |||||||
| Revenues |
||||||||
| Contract revenue |
$ | 449 | $ | 136 | ||||
| Grant revenue |
220 | 459 | ||||||
|
|
|
|
|
|||||
| Total revenues |
669 | 595 | ||||||
| Costs and expenses |
||||||||
| Research and development |
4,633 | 5,824 | ||||||
| General and administrative |
2,207 | 1,985 | ||||||
| Depreciation |
167 | 67 | ||||||
|
|
|
|
|
|||||
| Total costs and expenses |
7,007 | 7,876 | ||||||
|
|
|
|
|
|||||
| Loss from operations |
(6,338 | ) | (7,281 | ) | ||||
| Income from change in fair value of warrants |
— | 301 | ||||||
| Other income, net |
58 | 11 | ||||||
|
|
|
|
|
|||||
| Loss before income taxes |
(6,280 | ) | (6,969 | ) | ||||
| Income tax benefit |
13 | 13 | ||||||
|
|
|
|
|
|||||
| Net loss and comprehensive loss |
$ | (6,267 | ) | $ | (6,956 | ) | ||
|
|
|
|
|
|||||
| Net loss per share – Basic and Diluted |
$ | (0.06 | ) | $ | (0.08 | ) | ||
| Weighted average shares outstanding – Basic |
111,819,655 | 84,341,401 | ||||||
| Weighted average shares outstanding – Diluted |
111,819,655 | 85,416,506 | ||||||